Anticancer therapy
AssigneeBoehringer Ingelheim International GmbH
InventorsFlavio Solca, Ulrich Guertler, Michael Sanderson, Ulrike Tontsch-Grunt, Irene Waizenegger
Life of this patent
Estimating the term…
Abstract
The invention describes anti-cancer therapies comprising using dual Aurora kinase/MEK inhibitors as described herein.
Claims16
A method of treating a mammalian patient having cancer, said method comprising:
- obtaining a nucleic acid sample from a cancer sample from said patient;
- subjecting the sample to RAF or RAS mutational testing or PCR and identifying the presence of at least one mutation in the RAF or RAS gene;
- and
- administering an effective amount of a dual Aurora kinase/MEK inhibitor to the patient in whose sample the presence of at least one mutation in the RAF or RAS gene is identified.
(canceled)
A method of treating a mammalian, patient diagnosed with cancer which is dependent upon the MEK-signalling pathway or in which MEK is activated, in particular such cancer having at least one mutation in the BRAF or RAS (e.g. KRAS and/or NRAS) gene, said method comprising administering an effective amount of a dual Aurora kinase/MEK inhibitor.
14-16. (canceled)
17-19. (canceled)
20-40. (canceled)
Dependencies are inferred from the claim text.